UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of Report (Date of Earliest event Reported): July 23, 2014


                             LIFE STEM GENETICS INC.
             (Exact name of registrant as specified in its charter)

             Nevada                     333-183814                80-0832746
 (State or other jurisdiction of       (Commission              (IRS Employer
of incorporation or organization)      File Number)          Identification No.)

           433 North Camden Drive, Suite 400, Beverly Hills, CA 90210
                    (Address of principal executive offices)

                                 (310) 279-5234
              (Registrant's telephone number, including area code)

          (Former name or former address, if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications  pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule  14a-12  under the  Exchange  Act
    (17CFR240.14a-12)

[ ] Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
    Exchange Act (17CFR240.14d-2(b))

[ ] Pre-commencement  communications  pursuant  to Rule  13e-4(c)  under the
    Exchange Act (17CFR240.13e-4(c))

ITEM 1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT

We entered into an  agreement  dated July 23, 2014 with Prince  Marketing  Group
Limited.  Pursuant  to this  agreement  Prince  Marketing  agreed to sell to our
company  the rights to acquire a twenty  percent  ownership  interest  in a Cell
Culture and Tissue Engineering  Laboratory  established and owned by Dr. Roberto
Fernandez  Vina,  M.D.,  an  authority  on and provider of bone marrow stem cell
treatments. The Laboratory is located within the confines of Clinica San Nicolas
in San Nicolas de los Arroyos, Province of Buenos Aires, Argentina.

Pursuant  to the  agreement,  our company  will pay Prince  Marketing a purchase
price of $275,000 of which  $250,000  will be used to make  improvements  to the
Laboratory and $25,000 is a  non-refundable  deposit paid by way of a promissory
note payable on demand and bearing interest at the rate of ten percent per annum
compounded annually. The closing date of the agreement is October 15, 2014.

The agreement is  conditional  upon the company  completing an inspection of the
facility and other due diligence by September 30, 2014.

The agreement is further conditional that "...The Company will within 15 days of
the Effective Date provide  Prince with a copy of a termination  letter from the
Securities  and Exchange  Commission of the United States of America (the "SEC")
issued pursuant to S. 2.6.2 the SECURITIES AND EXCHANGE  COMMISSION  ENFORCEMENT
MANUAL published  October 9, 2013. The termination  letter is to include wording
to the effect that with respect to the Order of  Suspension of Trading of shares
of the  Company  issued  by the  SEC on  November  25,  2015,  the  Commission's
investigation  with regard to the Company is completed and they do not intend to
recommend any  enforcement  action by the  Commission.  If this condition is not
met, then the condition  completion date will  automatically  be extended to the
Closing Date,  however Prince shall then have the right to demand fulfillment of
the condition  within seven days, the fulfillment date to be calculated from and
including  the date of  notice.,,",  and "..."On or before  October 15, 2014 the
Company's  shares will be quoted for trading on a public stock exchange or stock
quotation system other than the Grays that is acceptable to Prince...."

Prince holds 3,202,036 shares of our Company's stock,  representing 6.98% of the
issued  shares.  The director of Prince,  Peter Merry,  has performed  legal and
consulting services on behalf of our Company.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

10.1    Agreement between our company and Prince Marketing Group Limited dated
        July 23, 2014

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated: July 23, 2014

LIFE STEM GENETICS INC.


By: /s/ Gloria Simov
   -----------------------------------------------
   Gloria Simov
   President, Chief Executive Officer and Director

                                       2